首页> 外文会议>Annual International Conference of the IEEE Engineering in Medicine and Biology Society >Predictive models for diffuse low-grade glioma patients under chemotherapy
【24h】

Predictive models for diffuse low-grade glioma patients under chemotherapy

机译:弥漫性低度神经胶质瘤患者接受化疗的预测模型

获取原文

摘要

Diffuse low-grade gliomas are rare primitive cerebral tumours of adults. These tumors progress continuously over time and then turn to a higher grade of malignancy associated with neurological disability, leading ultimately to death. Tumour size is one of the most important prognostic factors. Thus, it is of great importance to be able to assess the volume of the tumor during the patients' monitoring. MRI is nowadays the recommended modality to achieve this. Furthermore, if surgery remains the first option for diffuse low-grade gliomas, chemotherapy is increasingly used (before or after a possible surgery). However, crucial and difficult questions remain to be answered: identifying subgroups of patients who could benefit from chemotherapy, determining the best time to initiate chemotherapy, defining the duration of chemotherapy and evaluating the optimal time to perform surgery, or otherwise radiotherapy. In this study, we propose to help clinicians in decision-making, by designing new predictive models dedicated to the evolution of the diameter of the tumor. Two proposed statistical models (linear and exponential) have been validated on a database of 16 patients whose temozolomide-based chemotherapy lasted between 14 and 32 months, with an average duration of 22.8 months. The selection of the most appropriate model has been achieved with the corrected Akaike's Information Criterion. The results are very promising, with coefficients of determination varying from 0.79 to 0.97 with an average value of 0.90 for the linear model. This shows it is possible to alert the clinician to a change in the tumor diameter's dynamics.
机译:弥漫性低度神经胶质瘤是成人罕见的原始脑肿瘤。这些肿瘤会随着时间不断发展,然后发展为与神经功能障碍相关的更高级别的恶性肿瘤,最终导致死亡。肿瘤大小是最重要的预后因素之一。因此,在患者监测期间能够评估肿瘤的体积非常重要。如今,MRI是实现这一目标的推荐方式。此外,如果手术仍然是弥漫性低度神经胶质瘤的首选,那么化疗(在可能的手术之前或之后)将越来越多地被使用。但是,关键和困难的问题仍然有待回答:确定可以从化学疗法中受益的患者亚组,确定开始化学疗法的最佳时间,定义化学疗法的持续时间以及评估进行手术或其他放射疗法的最佳时间。在这项研究中,我们建议通过设计专门针对肿瘤直径演变的新预测模型来帮助临床医生进行决策。在数据库中验证了16个患者的两个拟议统计模型(线性和指数),这些患者的替莫唑胺类化学疗法持续时间为14到32个月,平均持续时间为22.8个月。通过更正的赤池信息准则,已经选择了最合适的模型。结果非常有希望,线性模型的测定系数从0.79到0.97不等,平均值为0.90。这表明可以警告临床医生肿瘤直径动态变化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号